Study selection and assessment: randomised controlled trials (RCTs) in any language that compared a single, fixed dose of prophylactic magnesium (intravenous, central, or intracoronary administration) with control (placebo or routine care) after cardiac surgery. 2 independent reviewers assessed the methodological quality of individual trials using the 5 point Jadad scale.
Outcomes: atrial fibrillation (AF), supraventricular arrhythmia (SA) and ventricular arrhythmia (VA), serum magnesium concentration on postoperative day 1, length of hospital stay, myocardial infarction (MI), and mortality.
MAIN RESULTS
17 RCTs (n = 2069) met the selection criteria. 9 studies had Jadad scores of 4-5 out of 5, and 8 studies had scores (3. Pooled serum magnesium concentration at 24 hours after surgery was higher in the magnesium group than in the control group (weighted mean difference [WMD] 1.1 mg/dl, 95% CI 0.7 to 1.4). Meta-analysis based on a random effects model showed that fewer patients who received magnesium had SAs, VAs, or AF compared with those who received the control intervention (table). The groups did not differ for length of hospital stay (7 trials, n = 1227, WMD 0.28 d, CI -0.70 to 1.27), perioperative MI (9 trials, n = 1191, relative risk [RR] 1.03, CI 0.52 to 2.05), or mortality (12 trials, n = 1588, RR 0.97, CI 0.43 to 2.20). Only 5 trials (n = 648) investigated side effects; no severe bradycardia or hypotension was reported.
CONCLUSIONS
Prophylactic treatment with magnesium after cardiac surgery is better than usual care or placebo for reducing the risk of atrial fibrillation and supraventricular and ventricular arrhythmias. Magnesium had no effect on length of hospital stay, myocardial infarction, or mortality. *Abbreviations defined in glossary; weighted event rates, RRR, NNT, and CI calculated from data in article using a random effects model.
Commentary
R esearch on the use of magnesium sulfate to suppress SAs and VAs in patients having cardiac surgery continues to provide conflicting results. The meta-analysis by Shiga et al establishes 2 points. Firstly, the findings of previous studies on the lack of effect of magnesium on patient mortality are supported; 1 the effect of magnesium on hospital length of stay and overall patient outcomes requires further study in a large multicentre trial.
2 In contrast to the findings of others, 3 Shiga et al confirm the prophylactic antiarrhythmic properties of magnesium. Secondly, although magnesium may be less potent than other medications (ie, b-blockers, amiodarone, and sotalol) for suppressing arrhythmias in cardiac surgery patients, it may also be associated with fewer harmful side effects. However, only 5 studies monitored side effects. Limitations of the review are the small number of studies that met the selection criteria and variability among studies in magnesium administration (ie, frequency and concomitant administration of other medications).
The results of the meta-analysis by Shiga et al are relevant to nurses caring for cardiac surgery patients. The findings establish realistic outcomes and risk considerations for magnesium treatment. This information will be useful to nurses in their efforts to collaborate with physicians to match drug effectiveness with patient needs. Patients who have off-pump coronary artery surgery have fewer episodes of postoperative AF 4 5 compared with on-pump patients and therefore may require a less potent drug or no prophylactic antiarrhythmics.
As operative approaches evolve, additional research will be needed to clarify the use of magnesium. Advanced practice nurses who are involved at the bedside in collaborative care efforts are in an ideal position to lead research efforts that investigate medication timing, prescribing differences, side effects, and patient outcomes.
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